63 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28049589	159	A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore.	Sri International
27171036	164	Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.	University of Nebraska Medical Center
26762835	342	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).	Icahn School of Medicine At Mount Sinai
26115571	38	Cyclin dependent kinase (CDK) inhibitors as anticancer drugs.	Eli Lilly
23301767	154	Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities.	University of Nottingham
23312943	166	Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase.	Pfizer
24900493	12	Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors.	TBA
18077363	314	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.	University of Oxford
21038853	133	4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6.	Novartis Institutes For Biomedical Research
18815031	41	Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors.	Astrazeneca
15999992	25	Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors.	Johnson & Johnson Pharmaceutical Research and Development
32184044	23	Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs.	Glaxosmithkline
32129996	166	Discovery and SARs of 5-Chloro-	Anhui Medical University
31477350	80	Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).	Eli Lilly
31382120	4	Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis.	Nankai University
31098000	63	Discovery of CDK5 Inhibitors through Structure-Guided Approach.	University of South Australia
31307887	64	Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.	Genentech
31693351	473	Discovery of 4	TBA
31376566	19	Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.	Nankai University
31381325	46	Discovery of Inhibitors of Aurora/PLK Targets as Anticancer Agents.	Chengdu University
30543440	86	Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.	University of South Australia Cancer Research Institute
30384048	365	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.	University of Florida
31670517	41	Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.	West China Hospital of Sichuan University
28156111	214	Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.	University of South Australia
31200237	95	Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.	Shanghai Pharmaceuticals Holding
30165341	72	Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors.	Jiangnan University
29247857	102	A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.	Beijing Normal University
29459274	69	Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapy.	Shanghai Haihe Pharmaceutical
29429832	77	Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.	Beijing University of Technology
29853338	31	Design, synthesis and biological evaluation of pyrimidine derivatives as novel CDK2 inhibitors that induce apoptosis and cell cycle arrest in breast cancer cells.	Shihezi University
28651979	6	Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate.	Nankai University
29370702	41	Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-Dependent Kinase Inhibitor.	Csir-Indian Institute of Integrative Medicine
28827110	54	Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors.	Korea Research Institute of Chemical Technology
29518312	78	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer.	Nankai University
28557430	45	Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule.	University of Kaiserslautern
16242653	33	A proteome-wide CDK/CRK-specific kinase inhibitor promotes tumor cell death in the absence of cell cycle progression.	Gpc Biotech